Kossel Medtech Secures Over RMB 100 Million in Series B Funding to Accelerate Global Vascular Intervention Platform

Dec 26, 2023 00:02 CST Updated 00:02

Kossel

Vascular Interventional Device Manufacturer and R&D Developer

Source of the article:Heart NotCome;Editor: Zhang Yuqing

Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

Heart Future

Recently,Kossel MedtechCompleted a Series B financing round exceeding 100 million yuan.This round of financing will help the company deepen its platformization and internationalization layout in vascular intervention, enrich its product pipeline, expand production bases, and attract talent.

# Company Introduction

Kossel Medtech (Suzhou) Co., Ltd. was established in November 2013.A platform enterprise with comprehensive R&D and production capabilities for vascular interventional devices,Dedicated to providing systematic solutions for clinical use.

The company focuses on building a one-stop treatment system in the field of peripheral intervention.Caval FilterIt is the 116th product approved through the NMPA's innovative medical device "green channel," with several other peripheral innovative products about to enter the clinical trial stage; Kossel is rapidly becoming a growing enterprise in the field of peripheral interventions.

Kossel has laid out multiple business sectors,Subsidiary Haiyu XinchengFocused on the field of electrophysiology, providing comprehensive solutions for the treatment of tachyarrhythmia, with core innovative products soon to enter clinical trials;Subsidiary Mixin MedicalFocus on the development of products in the coronary intervention field and the transformation of overseas products and technologies.

As a high-tech enterprise, Kossel possesses systematic independent innovation R&D capabilities and leading production and manufacturing capabilities, with nearly a hundred intellectual property rights already owned. Its products have successively passed ISO13485 and GMP certifications, and its coronary interventional products have obtained the EU CE, U.S. FDA, Japan PMDA, and South Korea KFDA registration certificates.

# Product Introduction

Peripheral Intervention:

Coronary Intervention:

Cardiac Electrophysiology:

# Other Information

As of the date of publication, the company's financing history is as follows:

As of the date of publication, the following partial patent information of the company has been queried:

Overseas Cardiovascular Devices:

Products of Chinese Cardiovascular Companies:

Editor-in-Chief | Zhao Qing Reviewed by | Yi He